NurExone Biologic Inc. NRXBF
Set alert
0.36 USD 0.00 0.00%
At close · Oct 30
0.36 Day range 0.36
0.3002 52-week range 0.535
- YTD
- -26.37%
- 1 year
- -25.00%
- Open
- 0.36
- Prev close
- 0.36
- Mkt cap
- 33.14M
- Vol
- 1.00K
- Avg vol
- 10.43K
- EPS
- -0.08
- P/E
- 0.00
More statistics
- Low
- 0.36
- High
- 0.36
3M chart
Signals (16)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 26, 2026 | 6 days ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 22, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
News
- NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes
- NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth
- NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update
- NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
- NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
- NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results
- NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
- NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy
- NurExone Announces Closing of C$1,066,078 Private Placement
- NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
Your note
Sign in to keep a note on NRXBF — it syncs with the Stock Master app.